Guangzhou Wondfo Biotech 万孚生物
21 significant filings since 31 May 2026: 13 on equity incentive, 4 on buyback and 3 on major holder buying, and 1 other kind. The latest, on 17 Sep 2026: 关于2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告.
自 31 May 2026 起有 21 份重大公告：equity incentive 13 份、buyback 4 份、major holder buying 3 份，另有 1 类。最新一份（17 Sep 2026）：关于2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥25.25 · Low 最低 ¥15.55The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 14 Apr 2020 | 民生证券 | 孙建,谭紫媚 | Outperform 增持 | ▲ | Buy 买入 |
| 11 Dec 2017 | 西南证券 | 朱国广,陈铁林,周平 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 信达证券 | 唐爱金 | Buy 买入 | 6 May 2026 | 1 | — |
| 开源证券 | 余汝意,陈峻,石启正 | Buy 买入 | 28 Apr 2026 | 1 | — |
| 太平洋 | 谭紫媚,李啸岩 | Buy 买入 | 18 Nov 2025 | 1 | — |
| 西南证券 | 杜向阳,陈辰 | Unrated | 29 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 4 reports. 每行为该券商近十二个月的最新研报；4 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。